Highlights PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:23 2026-03-05 am EST			5-day change	1st Jan Change
124.60 ^GBX	-0.80%		+1.47%	-0.32%

Feb. 20	Inflation's Reality Check
Feb. 20	PureTech says its pulmonary fibrosis drug granted orphan designation	AN

Highlights

Feb. 20	PureTech says its pulmonary fibrosis drug granted orphan designation	AN
Feb. 20	Risk on, risk off
Feb. 19	PureTech's deupirfenidone receives orphan drug status from US FDA, EU for pulmonary fibrosis	RE
Dec. 08	FDA backs PureTech's phase 3 move for IPF drug deupirfenidone	AN
Dec. 08	SMALL-CAP WINNERS: Mears rises as annual profit set to beat forecasts	AN
Dec. 08	PureTech Health plc Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis	CI
Dec. 05	London BTC continues work towards Nasdaq listing	AN
Nov. 03	Puretech's Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1B Trial of Lyt-200 in Relapsed/Refractory Acute Myeloid Leukemia At the American Society of Hematology Annual Meeting	CI
25-10-22	PureTech Health plc Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis	CI
25-09-29	PureTech Health plc Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100)	CI
25-08-28	PureTech Health half-year loss narrows on lower expenses	AN
25-08-28	PureTech Health plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-28	Earnings Flash (PRTC.L) PureTech Health Reports H1 Revenue $1.9M	MT
25-08-13	ITM Power agrees hydrogen deal; Aurrigo wins contract	AN
25-08-12	PureTech Health plc Announces the Launch of Celea Therapeutics	CI
25-07-16	PureTech Health CEO follows chair out door; Robert Lyne is interim CEO	AN
25-07-08	PureTech says Sharon Barber-Lui appointed interim board chair	RE
25-05-21	PureTech Health hails positive lung function results from drug trial	AN
25-05-21	Carr's proposes GBP70 million return	AN
25-05-20	PureTech?s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial	CI
25-05-09	PureTech Health plc Announces the Publication of New Research in BMC Pulmonary Medicine	CI
25-04-30	PureTech Health swings to profit in 2024, eyes long-term growth	AN
25-04-30	PureTech Health plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-07	PureTech Health Confirms Merger Talks with Nordic Capital	MT
25-04-07	PureTech Health confirms Nordic Capital bid interest	AN